Join the club for FREE to access the whole archive and other member benefits.

James Watson

UCLA academic plastic surgeon and a clinician with his own cosmetic clinic.

Dr. Watson is a board-certified Plastic Surgeon, formerly full time Associate Professor at UCLA Division of Plastic Surgery, which is the University where stem cells were first discovered in fat. In 2007, he left his full-time position at UCLA and co-founded University Stem Cell Center in Santa Monica, California, where he conducted the two of the first IRB-approved Phase I/II clinical trials in the US of autologous fat-derived stem cells for cosmetic and reconstructive surgery. These two clinical trials utilized fresh (not frozen) autologous adipose stem cells for enriched fat grafting and for intra-articular injections. Dr. Watson has co-founded a biotech company, Biostrux, designed to commercialize “point-of-care”, adipose-derived stem cells with a bioresorbable scaffold to do “in situ” tissue engineering utilizing autologous stem cells. Dr. Watson was successful in obtaining three Federally funded research grants from the DOD and NIH to develop the bioresorbable scaffold for Biostrux. More recently, Dr. Watson has re-focused his energy in exosome therapy and exosome research, as well as “next generation minimally invasive cosmetic surgery”. More recently, Dr. Watson has successfully completed two clinical trials in anti-aging therapies, utilizing Rapamycin and another clinical trial utilizing a triple cocktail of drugs and supplements that were shown to reverse epigenetic age in immune cells.

Visit website:

See also: Academia University of California, Los Angeles (UCLA) - Public land-grant research university

Details last updated 26-May-2021

James Watson is also referenced in the following:

Ask Me Anything (AMA) with The PEARL Team


Find out more about the Participatory Evaluation of Aging with Rapamycin for Longevity Study (FREE)

James Watson News crowd-funds clinical trial to determine the effects of Rapamycin (LEAF) - 17-May-2021

PEARL: Participatory Evaluation of Aging with Rapamycin for Longevity